SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Stateside's Canadian Microcap Board
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dave@SI who wrote (1690)9/23/2016 12:30:05 PM
From: ayeyou  Read Replies (1) of 1728
 
Thanks for that Dave. I think you right on the delay thing as BCT has stated that they intend to use the gene marker in its BriaDX diagnostics for selecting patients. What ever they decide to do I really wish they would just do it as the constant delays although to be expected in pharma trials is nonetheless a anchor on the share price. I have come real close to adding to my position lately but the uncertainty of when these trials will get started have held me back. Will add if it should fall below .20 again. I am ready for next round of action with BCT. I really think the trials will go great and all these months of waiting will be well rewarded.

Understanding the mechanism of action (MOA) of BriaVax, that is how the vaccine works, is a critical component of the path to BriaDx, a companion diagnostic for prospectively identifying patients with a high likelihood of benefiting from BriaVax. The company believes that the discovered gene signature is a crucial element in the MOA and could thus support BriaCell's efforts in identifying patients for whom BriaVax may be most efficacious. BriaCell's mission is to serve late-stage cancer patients with no other treatment options. The company hopes to offer an attractive alternative, one which would combine the BriaDx companion diagnostic together with the BriaVax cancer vaccine. Identifying those patients most likely to benefit from BriaVax would only serve to enhance the lives of patients by offering a more comprehensive solution with a higher success rate.

stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News